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Introduction
Chronic myeloproliferative hemopathies (CMPH) as a 
whole are the most common chronic leukemias in the el-
derlies in the structure of morbidity by hematological ma-
lignancies with primary bone marrow involvement, being 
characterized in the advanced stages by a severe, recur-
rent evolution and unfavorable prognosis, with negative 
socio-economic impact [1-5, 7]. Chronic myeloid leukemia 
(CML), primary myelofibrosis (PMF) and polycythemia 
vera (PV) are considered the most common CMPH. CML is 
a clonal neoplastic pathology of the hematopoietic system, 
which results from the malignant transformation of the plu-
ripotent stem cell, while maintaining the ability of differen-
tiation into all cell lines [6-9]. CML morbidity increases with 
age, with a maximum incidence between 35 and 65 years 
(median age – 53 years), that indicates the predominant 
involvement of the workable population. CML morbidity 
varies between 1.0-2.0 cases per 100000 of population. The 
clinico-evolutional and hematologic patterns of CML com-
prise splenomegaly, myeloid hyperplasia of the bone mar-
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Abstract
Background: Chronic myeloproliferative hemopathies (CMPH) as a whole are the most common chronic leukemias in the elderly in the structure of 
morbidity by hematological malignancies with primary bone marrow involvement, being characterized in the advanced stages by a severe, recurrent 
evolution and unfavorable prognosis, with negative socio-economic impact. 
Material and methods: A clinical, analytical, and descriptive study was carried out along with the narrative review of the international literature 
on the subject. The study enrolled 91 elderly patients with different phases of chronic myeloid leukemia (CML), primary myelofibrosis (PMF) and 
polycythemia vera (PV), who were followed up and treated at the Institute of Oncology in the period of 1995–2020. According to the impact score, 25 
relevant primary sources were identified and selected having a scientific, reproducible and transparent approach to the relevant subject, followed by data 
extraction and analysis. 
Results: The overall one- and 5-year survival in patients aged greater than or equal to 60 years old treated with tyrosine kinase inhibitors (TKIs) was 97.6 
and 79%, being lower as compared with the same indices in the totality of CML. In elderly PV patients the overall 5-and 10-year survival made up 93.5% 
and 76.4%, being lesser than registered in all patients with PV. As reported in the recent references, a significant rate of patients with CMPH underwent 
reduced working hours, discontinued employment, and medical disability: PMF – 38%, 35%, 33%, and PV – 33%, 28%, and 15%, respectively.
Conclusions: The long-term treatment results in elderly patients with CMPH fail compared to those in the CMPH totality, due to the development of 
age-related diseases and vascular accidents caused by leuko- and thrombocytosis.   
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row, hypercatabolic symptoms and progression to the acute 
leukemia in the majority of cases. PMF represents a chronic 
myeloproliferative neoplasm, which derives from the clonal 
myeloid prolifetaion as a result of malignant transformation 
of stem cell. The disease is manifested by splenomegaly, bone 
marrow fibrosis, anemia, extramedullary hematopoiesis, 
tendency to cachexia and blastic transformation. According 
to the majority of references, the incidence of PMF consti-
tutes 0.7-1 case per 100000 of population [1, 3, 4]. In 67% 
of cases PMF is diagnosed in persons over 54 years old.  PV 
is a clonal trilineage proliferation of the malignized hema-
topoietic stem cell, being characterized by blood hypervis-
cosity and increased risk of thromboses. The estimated inci-
dence of PV per 100000 of population ranges from 0.4 to 2.8 
cases in Europe and from 0.8 to 1.3 cases in the USA. The 
reported age median encompasses 65-70 years. The bone 
marrow is hypercellular and exhibits hyperplasia of my-
eloid, erythroid, and megakaryocyte lineages. Erithrocyte 
formation is predominantly increased. The symptoms and 
signs of PV can be attributed in large part to the expanded 
total blood volume and to the slowing blood flow as a result 
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of increased blood viscosity. The latent thrombogenic status 
occurs. Arterial hypertension commonly develops. PV and 
PMF are considered orphan diseases in the USA because 
they affect less than 200000 people regardless of the obser-
vation period [10]. Marketology researches have shown that 
in 2003 the prevalence per 100000 population of  PV was 22 
and PMF – 19. The development and increased prevalence 
of CMPH in the elderlies correlates with the demographic 
aging process in the USA and the European Union [11], in 
which the rate of the population over 80 years old will triple 
with predictability between 2011 and 2060.
Patients across all CMPH experience a marked disease 
burden in terms of symptoms and negative effects on quality 
of life, productivity, and daily living activities. It is impor-
tant to have an updated and appropriate understanding of 
these burdens from a financial standpoint in order to im-
prove the health and life quality of patients with CMPH.   
Predominantly late diagnosis, increased degree of disability, 
morbidity and mortality indices in the age categories greater 
than or equal to 60 years [2, 11] identify CMPH as an actual 
problem of public health and clinical hematology. 
Material and methods
A clinical, analytical and descriptive study was carri-
ed out along with a narrative review of the international 
literature regarding this subject. The study enrolled 91 
elderly patients with different phases of chronic myeloid 
leukemia (CML), primary myelofibrosis (PMF) and polycy-
themia vera (PV), who were followed up and treated at the 
PMSI Institute of Oncology in the period of 1995 – 2020. 
The following research methods were used: epidemiologi-
cal, descriptive, comparative, clinical-analytical, and cohort 
statistics [12]. The type of CMPH was identified accord-
ing to the Revised 2017 WHO Classification of Tumors of 
Hematopoietic and Lymphoid Tissues [13-15]. The diag-
nosis was confirmed via histopathological, cytological, cy-
togenetic and molecular examinations of the bone marrow 
and peripheral blood [1, 5, 6, 8, 9, 15, 16]. The quantitati-
ve real-time PCR was used to detemine  the expression of 
the  BCR-ABL chimeric gene  p210 and p190 transcripts 
while proceeding CML diagnosis. Five transcription pro-
ducts (b2a2, b3a2, b2a3, b3a3 and  e1a2) were analyzed by 
using  the quantitative PCR test [8]. The quantitative  de-
tection of  JAK2 V617F mutation served as a major crite-
rion in the diagnostically unasserted  cases of PV and PMF. 
CML patients underwent TKI single-agent chemotherapy. 
The first-line treatment of PMF and PV patients included a 
single-agent conventional chemotherapy with busulfan and 
hydroxycarbamide. The research data collection was carried 
out by analyzing information provided by the international 
scientific sources and official statistics related to the above 
mentioned nosological entities. More than 50 reference 
bibliographic sources have been studied. According to the 
impact score, 25 relevant primary sources were identified 
and selected with a scientific, reproducible and transparent 
approach regarding this relevant subject, followed by data 
extraction and analysis. To minimize the error, a copy of the 
data extraction sheet was initially obtained, listing all the 
elements that should be extracted from the primary studies. 
When doing the qualitative research, a narrative synthesis of 
data has been performed.
Results and discussion
Thirty-four (37.3%) patients with PMF, 26 (28.6%) – 
with CML and 31 (34.1%) – with PV were diagnosed in 
the elderly age groups and followed up by our study. The 
prefibrotic stage of PMF was confirmed in 15 (44.1%) ca-
ses, fibrotic stage – in 21 (55.9%). The diagnosis of CML 
was made in 24 (92.3%) patients in chronic phase and in 
2 (7.7%) patients in accelerated phase. In all cases PV was 
diagnosed in the erythremic stage: II A – in 27 (87.1%) pa-
tients, IIB – in 4 (12.9%). The age group of 60-69 years was 
more numerous in CML (22 cases, or 84.6%), accounting 
for 25 (80.6%) cases in PV and 25 (73.5%) cases in PMF. The 
duration of the disease from the time of onset of the initial 
clinical symptoms to diagnosis ranged in PMF between 1.4-
7 months (on average – 3.7±0.63 months), in CML between 
1.5-12 months (on average – 2.1±0.37 months) and in PV 
between 1-7 months (on average – 3.8±0.54 months). The 
clinical onset and addressability of patients with CML and 
PMF did not differ significantly, most patients (over 90%) 
being consulted by a family doctor because of the presen-
ting complaints such as  fatigue, heaviness and then pain in 
the left hypochondrium or in the left hemiabdomen. Most 
patients with PV (21 persons or 67.7%) went to the territo-
rial healthcare institutions for medical assistance, complain-
ing of steady hypertension or so-called “astheno-vegetative” 
syndrome. In 3 (9.7%) cases the diagnosis of PV was made, 
following a treatment for myocardial infarction within the 
cardiology wards. Two (6.5%) patients diagnosed with isch-
emic stroke were hospitalized at the neurology wards for 
emergency medical care; the diagnosis of PV was further 
confirmed. 
According to the references updates, the mean life 
span of CML patients under the conventional chemother-
apy ranges between 4-5 years, exceeding 10 years in 30% 
of them. Although the allogeneic hematopoietic stem cell 
transplantation is considered in many instances as the most 
efficient treatment option, with a potential of complete re-
covery, especially in cases refractory to TKIs, it remains cur-
rently inapplicable in the elderly CML patients [9, 16, 17]. 
Regardless the age, recombinant interferon α (IFN α-2b) 
preserves its role as a valid treatment option in chronic 
phase of CML, committing to the achievement of complete 
hematologic response in 81% of cases [18].  Under the treat-
ment with IFN α-2b the major cytogenetic response may 
be obtained in 40% and complete cytogenetic response in 
25% of CML patients. The overall 5-year survival of patients 
treated with IFN α-2b is rated at 57%, being superior to that 
one in patients managed with conventional chemotherapy 
(42%). This present  study showed no significant difference 
in the rate of complete clinical-hematological (92.3% vs 
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92.8%) and complete molecular response (23.1% vs 24.7%) 
under TKIs medication between elderly patients and to-
tal number of CML patients. The overall one- and 5-year 
survival in elderly patients treated with TKI was 97.6% and 
79%, being comparable with the respective parameters in all 
CML patients (98.5% and 87%, correspondingly). IFN α-2b 
was used in rare cases of resistance to conventional chemo-
therapy and TKIs, showing a partial response. 
A combination of chemotherapy and phlebotomies 
was used in all 31 patients with PV that led to a clinical-
hematological remission. The response duration ranged 
from 3 to 9 months (on average – 5.8 months). The disease 
relapsed in all cases of plethoric syndrome and thrombocy-
tosis, which required the resumption of induction chemo-
therapy with busulfan and hydroxycarbamide, followed by 
regaining remissions. Fatal cases associated with the treat-
ment and thromboembolic complications did not occur. 
The over one-year overall survival in elderly patients consti-
tuted 100%, over 5 years – 93.5% and over 10 years – 76.4%, 
thus exhibiting a lower rate than those registered in all PV 
patients (over one year – 100%, 5 years – 98.6%, 10 years 
– 85.9%). Although the relapse rate was lower in patients 
treated with busulfan as compared to those managed with 
hydroxycarbamide, there was no significant difference in 
the overall survival of the elderly patients undergoing che-
motherapy with these antineoplastic agents. 
The recent literature sources consider single-agent 
chemotherapy with hydroxycarbamide as the first-line 
treatment option in the elderly with PMF, associated with 
splenomegaly and thrombocytosis. Thalidomide or lena-
lidomide in combination with prednisolone, danazol may 
be administered in cases with marked symptoms, especially 
in those with splenomegaly and anemia. The patients with 
intermediary-2 risk, especially those with prognostically 
unfavorable mutations ASXL1, SRSF2 and aged ≥ 65 years 
old, should be administered  treatment with JAK kinase in-
hibitors (ruxolitinib, etc.). In most studies the mean survival 
rate is estimated to  3.5-5 years, ranging from 1 year in some 
patients to even decades in others. According to the inter-
national literature data, the survival rate in PMF (on average 
– 5.9 years)  is still lower compared  to the same indicator in 
other Ph-negative CMPH like PV (on average – 13.5 years) 
and ET  (on average – 19.8 years) [19]. This study reported 
on the rate of clinical -hematological responses (73.5%) and 
survival rate under busulfan and hydroxycarbamide treat-
ment in patients with PMF, which were also lower than in 
PV and CML. The 5-year overall survival of elderly PMF 
patients, constituted 67% and proved to be lower, if com-
pared to the mean 5.9-year survival in all  PMF patients, 
thus showing similar data as reported by other relevant 
studies. [20-22]. Only three PMF patients, diagnosed in 
2001, 2007 and 2009 respectively, are being followed up. 
Generally, this suggested that new therapies may be recom-
mended in CMPH at any age without absolute contraindica-
tions. An individual precise therapy should be mandatorily 
considered for every patient [17, 23]. In PMF and PV cases, 
refractory or intolerant to hydroxycarbamide, COMFORT 
and RESPONSE studies showed the rate of 41.9-62% of 
disease control under the treatment with JAK inhibitors, 
as compared with the best available therapy (0-19%).  For 
these reasons, an accurate definition of diagnosis and prog-
nostication is required. Precision in CMPH definition and 
prognostication is decisively useful for a customized  thera-
peutic approach [17].
In order to assess the financial burden of CMPH on pub-
lic health, the narrative review of the international experi-
ence was performed. A study on financial burden of CMPH 
on patients was carried out in the USA in 2014 [24]. The 
subjects who were diagnosed before 2013, aged between 16-
65 old at the time of diagnosis were eligible for this analysis 
(PMF – 85, PV – 172). Almost all patients (99%) had health 
insurance, primarily group commercial insurance through 
an employer (PMF – 46%, PV – 53%) and Medicare (PMF – 
40%, PV – 34%). The mean 2013 household incomes of pa-
tients with PMF and PV were similar to each other ($79800, 
and $80200, respectively) and slightly higher than the total 
2013 USA mean household income of $75839. A significant 
rate of patients in each CMPH group reported that their dis-
ease led to reduced work hours, discontinued employment, 
and medical disability: PMF – 38%, 35%, 33%, and PV – 
33%, 28%, and 15%, respectively. Patients, demographic fea-
tures, such as age and health insurance status, were similar 
among patients who reported CMPH-associated effects on 
employment and patients who did not report these within 
each CMPH case. In each CMPH group, the mean percent-
age household income loss in patients with reduced work 
hours, discontinued employment, and medical disability 
were: PMF – 16%, 18%, 28%, and PV – 15%, 24%, 17%, re-
spectively, compared with patients who did not experience 
any effects of their CMPH on employment. Discontinued 
employment and medical disability, especially in elderly pa-
tients, tended to have a greater negative impact compared 
with reduced work hours across CMPH [24, 25].
Conclusions
The long-term treatment results in elderly patients with 
CMPH fail compared to those of overall CMPH cases, be-
cause of the development of age-related diseases and vas-
cular accidents due to leuko- and thrombocytosis. The 
slow onset, gradual increase of hemoglobin, erythrocyte 
count and blood viscosity along with inappropriate onco-
logic vigilance of primary care doctors may lead to the oc-
currence of thrombotic and vascular complications in the 
elderly PV patients. The targeted treatment with TKIs re-
mains a therapeutic option of choice for CML patients aged 
over 60 years old. In the elderly PV patients, no significant 
difference was revealed in short- and long-term outcomes 
of chemotherapy with busulfan and hydroxycarbamide in 
combination with phlebotomy, thus providing better overall 
results than  those used in PMF patients. The review of the 
literature shows that the patients with CMPH, especially the 
elderly ones, may suffer a considerable unfavorable impact 
of their employment status, which in turn may be associ-
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ated with a reduced annual household income. Prevention 
or backtracking discrete aspects of CMPH, that negatively 
impact individual productiveness, may be considered as an 
important factor in the management of these diseases.
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